CR20230219A - Polipéptidos de interleucina-2 mutante dependientes del ph - Google Patents

Polipéptidos de interleucina-2 mutante dependientes del ph

Info

Publication number
CR20230219A
CR20230219A CR20230219A CR20230219A CR20230219A CR 20230219 A CR20230219 A CR 20230219A CR 20230219 A CR20230219 A CR 20230219A CR 20230219 A CR20230219 A CR 20230219A CR 20230219 A CR20230219 A CR 20230219A
Authority
CR
Costa Rica
Prior art keywords
polypeptides
dependent mutant
immunoconjugates
dependent
mutant interleukin
Prior art date
Application number
CR20230219A
Other languages
English (en)
Inventor
Christian Gassner
Lorenzo Dehò
Pablo Umaña
Sylvia Herter
Ralf Hosse
Adrian Hugenmatter
Christian Klein
Bianca Scherer
Ekkehard Moessner
Thomas Hofer
Florian Limani
Melanie Obba
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CR20230219A publication Critical patent/CR20230219A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere en general a polipéptidos de interleucina-2 mutante dependientes del pH que exhiben una unión reducida al receptor de IL-2 a pH neutro y retienen la unión al receptor de IL-2 a pH reducido. Además, la invención se refiere a inmunoconjugados que comprenden dichos polipéptidos de IL-2 mutante dependientes del pH, moléculas de polinucleótidos que codifican los polipéptidos de IL-2 mutante dependientes del pH o inmunoconjugados, y vectores y células huésped que comprenden tales moléculas de polinucleótidos. La invención se refiere además a métodos para producir los polipéptidos de IL-2 mutante dependientes del pH o inmunoconjugados, composiciones farmacéuticas que los comprenden y usos de estos.
CR20230219A 2020-12-04 2021-12-02 Polipéptidos de interleucina-2 mutante dependientes del ph CR20230219A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20211731 2020-12-04
PCT/EP2021/083864 WO2022117692A2 (en) 2020-12-04 2021-12-02 Ph-dependent mutant interleukin-2 polypeptides

Publications (1)

Publication Number Publication Date
CR20230219A true CR20230219A (es) 2023-07-07

Family

ID=73726565

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20230219A CR20230219A (es) 2020-12-04 2021-12-02 Polipéptidos de interleucina-2 mutante dependientes del ph

Country Status (15)

Country Link
US (1) US20240092853A1 (es)
EP (1) EP4255923A2 (es)
JP (1) JP2023551563A (es)
KR (1) KR20230117122A (es)
CN (1) CN116635403A (es)
AR (2) AR124246A1 (es)
AU (1) AU2021393752A1 (es)
CA (1) CA3197740A1 (es)
CO (1) CO2023007108A2 (es)
CR (1) CR20230219A (es)
IL (1) IL303381A (es)
MX (1) MX2023006480A (es)
PE (1) PE20232045A1 (es)
TW (1) TW202237632A (es)
WO (1) WO2022117692A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL298136A (en) 2020-05-13 2023-01-01 Bonum Therapeutics Inc Preparations of protein complexes and methods of using them
TW202406932A (zh) 2020-10-22 2024-02-16 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
WO2025242835A1 (en) 2024-05-22 2025-11-27 Ose Immunotherapeutics Molecules comprising masking linkers and uses thereof for the treatment of cancer

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2388385B1 (fr) 1977-04-18 1982-01-08 Hitachi Metals Ltd Piece d'ornement fixee par des aimants permanents
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US4604377A (en) 1984-03-28 1986-08-05 Cetus Corporation Pharmaceutical compositions of microbially produced interleukin-2
US5116943A (en) 1985-01-18 1992-05-26 Cetus Corporation Oxidation-resistant muteins of Il-2 and other protein
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
JP2524586B2 (ja) 1985-06-26 1996-08-14 シタス コーポレイション ポリマ−接合を利用する医薬組成物用蛋白質の可溶化
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
FI941572A7 (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
US5229109A (en) 1992-04-14 1993-07-20 Board Of Regents, The University Of Texas System Low toxicity interleukin-2 analogues for use in immunotherapy
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
DK1034298T3 (da) 1997-12-05 2012-01-30 Scripps Research Inst Humanisering af murint antistof
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
ES2248127T3 (es) 1999-10-04 2006-03-16 Medicago Inc. Metodo para regular la transcripcion de genes foraneos en presencia de nigtrogeno.
WO2003015697A2 (en) 2001-08-13 2003-02-27 University Of Southern California Interleukin-2 mutants with reduced toxicity
DK1454138T3 (da) 2001-12-04 2012-02-13 Merck Patent Gmbh Immunocytokiner med moduleret selektivitet
US7432063B2 (en) 2002-02-14 2008-10-07 Kalobios Pharmaceuticals, Inc. Methods for affinity maturation
US20060234205A1 (en) * 2004-03-05 2006-10-19 Chiron Corporation In vitro test system for predicting patient tolerability of therapeutic agents
EP1740615B1 (en) 2004-03-31 2014-11-05 Genentech, Inc. Humanized anti-tgf-beta antibodies
CA2648484A1 (en) 2006-05-08 2007-11-15 Philogen Spa Antibody-targeted cytokines for therapy
ES2368868T3 (es) 2006-09-20 2011-11-23 Mt-Biomethan Gmbh Procedimiento y dispositivo para la separación de metano y dióxido de carbono de biogás.
WO2009061853A2 (en) 2007-11-05 2009-05-14 Massachusetts Institute Of Technology Mutant interleukin-2 (il-2) polypeptides
JP6157046B2 (ja) 2008-01-07 2017-07-05 アムジェン インコーポレイテッド 静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法
JP5764127B2 (ja) 2009-08-17 2015-08-12 ロシュ グリクアート アーゲー 標的化イムノコンジュゲート
SG192673A1 (en) 2011-02-10 2013-09-30 Roche Glycart Ag Mutant interleukin-2 polypeptides
PT3102595T (pt) * 2014-02-06 2019-01-11 Hoffmann La Roche Proteínas de fusão de interleucina-2 e suas utilizações
MY201482A (en) * 2017-04-03 2024-02-26 Hoffmann La Roche Immunoconjugates of an anti-pd-1 antibody with a mutant il-2 or with il-15

Also Published As

Publication number Publication date
MX2023006480A (es) 2023-06-19
US20240092853A1 (en) 2024-03-21
AR124246A1 (es) 2023-03-01
JP2023551563A (ja) 2023-12-08
WO2022117692A2 (en) 2022-06-09
WO2022117692A3 (en) 2022-10-20
CO2023007108A2 (es) 2023-06-30
KR20230117122A (ko) 2023-08-07
EP4255923A2 (en) 2023-10-11
AU2021393752A1 (en) 2023-05-18
TW202237632A (zh) 2022-10-01
AR129131A2 (es) 2024-07-17
CN116635403A (zh) 2023-08-22
IL303381A (en) 2023-08-01
PE20232045A1 (es) 2023-12-27
CA3197740A1 (en) 2022-06-09

Similar Documents

Publication Publication Date Title
MX2023006480A (es) Polipeptidos de interleucina-2 mutante dependientes del ph.
PH12022552436A1 (en) Immunoconjugates
MX2019011770A (es) Inmunoconjugados de un anticuerpo anti-pd-1 con un mutante il-2 o con il-15.
MA35803B1 (fr) Polypeptides d'interleukine-2 mutants
PH12019501056A1 (en) Conjugation linkers, cell binding molecule-drug conjugates containing the likers, methods of making and uses such conjugates with the linkers
ZA201905462B (en) Proteins binding her2, nkg2d and cd16
MX2021007085A (es) Variante de interleucina-2 humana o derivado de la misma.
WO2021007428A3 (en) Molecules, compositions and methods for treatment of cancer
AR119338A1 (es) Inmunoconjugados que comprenden un polipéptido interleuquina-2 (il-2) mutante y un anticuerpo que se une a cd8
MX2024007966A (es) Anticuerpos anti-tslp novedosos.
WO2021158619A8 (en) IL-7Rα BINDING COMPOUNDS
WO2021212083A3 (en) Engineered il-12 and il-23 polypeptides and uses thereof
MX2024010472A (es) Polipeptidos que enlazan adamts5, mmp13 y agrecano.
SG10201708038QA (en) Improved nanobodies™ against tumor necrosis factor-alpha
PH12022551462A1 (en) Ilt3-binding agents and methods of use thereof
WO2021262597A3 (en) Lair-1-binding agents and methods of use thereof
MX2019009541A (es) Proteinas que se unen a psma, nkg2d y cd16.
MX2019009943A (es) Proteínas que se unen a gd2, nkg2d y cd16.
MX2021000323A (es) Enzimas de variante de pantotenato quinasa modificadas geneticamente.
ZA202402492B (en) New interleukin-7 immunoconjugates
MX2023005180A (es) Compuestos de union a il-2r\03b2?c y usos de estos.
MX2022007960A (es) Nuevos anticuerpos anti-fgfr2b.
MX2024014830A (es) Compuestos de degradacion de wee1 y usos de los mismos
WO2023081766A3 (en) Antibody-drug conjugates against the receptor tyrosine kinase epha5
MX2023008598A (es) Agentes de interleuquina-2 y usos de los mismos.